Greenwich LifeSciences, Inc (GLSI)

Etorro trading 970x250

About Greenwich LifeSciences, Inc

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing (HER2/neu) cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is headquartered in Stafford, Texas. Address: Building 14, Stafford, TX, United States, 77477

Greenwich LifeSciences, Inc News and around…

Latest news about Greenwich LifeSciences, Inc (GLSI) common stock and company :

Will Insiders Be Tempted To Buy More GLSI At The New 52-Week Low?
14 Jan, 2022 FinancialContent

In trading on Friday, shares of Greenwich LifeSciences Inc (GLSI) touched a new 52-week low of $19.22/share. That's a $50.55 share price drop, or -72.45% decline from the 52-week high of $69.77 set back on 04/09/2021..

Peek Under The Hood: DWAS Has 35% Upside
17 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $114.43 per unit.

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
15 Dec, 2021 FinancialContent

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings
09 Dec, 2021 FinancialContent

Greenwich LifeSciences Inc(NASDAQ: GLSI) has published newGP2 Phase 2b trial data. The trial enrolled HER2 positive ...

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
09 Dec, 2021 FinancialContent

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
08 Dec, 2021 FinancialContent

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
07 Dec, 2021 FinancialContent

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
06 Dec, 2021 FinancialContent

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

58 Biggest Movers From Friday
06 Dec, 2021 FinancialContent

Gainers Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62. TuanChe Limited (NASDAQ: TC) gained 44.7% to settle ...

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
18 Nov, 2021 FinancialContent

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
17 Nov, 2021 FinancialContent

Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference

Implied DWAS Analyst Target Price: $111
11 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $111.40 per unit.

Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
11 Nov, 2021 FinancialContent

Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
10 Nov, 2021 FinancialContent

Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
09 Nov, 2021 FinancialContent

Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts

Greenwich LifeSciences Enters Oversold Territory (GLSI)
27 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI
20 Oct, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - October 20, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/greenwich-lifesciences-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsi

The Moonshot Investor: The Insider Track Strategy
08 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung’s Moonshot Investor series. Investors interested in finding stocks with 100x potential or more can subscribe to Tom’s mailing list here. If You Can’t Beat Insiders… Why Not Join Them? Source: Chad McDermott / Shutterstock.com It was a.... The post The Moonshot Investor: The Insider Track Strategy appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

A Controversial Moonshot Stock Just Got a Lot More Interesting
08 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Studies have found that insiders outperform the market by 6-15%. Over a long period, that's an incredible achievement and worth understanding. The post A Controversial Moonshot Stock Just Got a Lot More Interesting appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Analysts Predict 11% Gains Ahead For DWAS
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $101.18 per unit.

3 Stocks Insiders Are Snapping Up. Do They Know Something We Don’t?
05 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits. The post 3 Stocks Insiders Are Snapping Up. Do They Know Something We Don’t? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Here's What Greenwich LifeSciences, Inc.'s (NASDAQ:GLSI) Shareholder Ownership Structure Looks Like
01 Oct, 2021 Yahoo! Finance

The big shareholder groups in Greenwich LifeSciences, Inc. ( NASDAQ:GLSI ) have power over the company. Generally...

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
28 Sep, 2021 FinancialContent

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
27 Sep, 2021 FinancialContent

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
23 Sep, 2021 FinancialContent

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
13 Sep, 2021 FinancialContent

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
09 Sep, 2021 FinancialContent

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
07 Sep, 2021 FinancialContent

Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021
01 Sep, 2021 FinancialContent

Upgrades For Chatham Lodging Trust (NYSE:CLDT), Barclays upgraded the previous rating of Equal-Weight to Overweight. In ...

Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
17 Aug, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Greenwich LifeSciences, Inc (GLSI) is a NASDAQ Common Stock listed in , ,

970x250